©2022 Stanford Medicine
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders
Not Recruiting
Trial ID: NCT00186576
Purpose
To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic
hematopoietic cell transplant.
Official Title
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)
Stanford Investigator(s)
Laura Johnston
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Robert Negrin
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- HLA matched donor available Exclusion Criteria:- organ dysfunction
- HIV positive
Intervention(s):
procedure: nonmyeloablative allogeneic hematopoietic cell transplant
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822